Search for clinical trials in your area or further afield. We recommend speaking to your medical team if you find a trial you think you may be eligible for.
The research is looking into patients’ experiences of radiotherapy treatment for gynaecological cancers with the aim to: increase understanding of how radiotherapy impacts on social, personal and sexual lives and longer-term post-treatment experiences of gynaecological cancer explore the experiences of those who are/have been carers or sign…
In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments. The drugs involved in this trial: Rucaparib – a targeted treatment known as a PARP inhibitor Paclitaxel – a sta…
The main purpose of conducting the trial is to: determine the safety of combining cediranib, a VEGF inhibitor, with paclitaxel a weekly chemotherapy regime find out how well the treatment works in terms of shrinking the cancer and preventing bowel obstruction. If the cancer responds to this treatment then after the course of paclitaxel…
The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…
This study is looking at using a drug called TAK228 (new drug) in combination with paclitaxel (a standard chemotherapy drug) to see if it's a more effective way of treating ovarian cancer. The drugs involved in this trial are: TAK228 (new drug) – a drug that is thought to interfere with cell growth and may slow or stop cancer cells from di…
This study collects information about people who have inherited faulty cancer genes. Inheriting a faulty gene means that a person is at a higher risk of developing certain cancers. A fault in the BRCA1 or BRCA2 genes means that a person is more likely to develop cancers of the breast, ovary or prostate. As well as the BRCA1 and BRCA2 genes, we n…
Sign up to receive emails from Target Ovarian Cancer, including our monthly newsletter, and be the first to hear about campaigns, upcoming events and fundraising inspiration.
Sign up
